Lilly Says Its Obesity Drugs Helped Patients Lose Weight in Clinical Trials
4 Articles
4 Articles
Lilly says its obesity drugs helped patients lose weight in clinical trials - Regional Media News
Nov 14 (Reuters) - Eli Lilly & Co on Saturday released some new data from several clinical trials of its obesity drugs for the ObesityWeek 2026 medical conference, but it has not yet released the full results. In the Phase 2 trial of EloraTZP, an [...]
Lilly says its obesity drugs helped patients lose weight in clinical trials
Nov 14 (Reuters) - Eli Lilly & Co on Saturday released some new data from several clinical trials of its obesity drugs for the ObesityWeek 2026 medical conference, but it has not yet released the full results. In the Phase 2 trial of EloraTZP, an in...
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale - PressReach
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity People reported Foundayo … Continue reading "L…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
